ORTHO-RHUMATO | VOL 12 | N°1 | 2014
22
11. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid
arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann
Rheum Dis 2010;69(6):1129-35
12. Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the
e cacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PloS
one 2012;7(1):e30275.
13. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-
tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-
controlled, phase III trial evaluating primary e cacy and safety at twenty-four weeks. Arthritis
Rheum 2006;54(9):2793-806.
14. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves
treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis
factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Ann Rheum Dis 2008;67(11):1516-23.
15. Genovese MC, Becker JC, Schi M, et al. Abatacept for rheumatoid arthritis refractory to tumor
necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23.
16. Moreland LW, Pratt PW, Mayes MD, et al. Double-blind, placebo-controlled multicenter trial
using chimeric monoclonal anti-Cd4 antibody, Cm-T412, in rheumatoid-arthritis patients
receiving concomitant methotrexate. Arthritis Rheum 1995;38(11):1581-8.
17. Wendling D, Racadot E, Wijdenes J, et al. A randomized, double blind, placebo controlled
multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J
Rheumatol 1998;25(8):1457-61.
18. van der Lubbe PA, Dijkmans BA, Markusse HM, et al. A randomized, double-blind, placebo-
controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis
and rheumatism 1995;38(8):1097-106.
19. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. CAMPATH-1H, a humanized monoclonal antibody,
in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum
1995;38(11):1589-94.
20. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural
damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann
Rheum Dis 2008;67(8):1084-9.
21. Melis L, Vandooren B, Kruithof E, et al. Systemic levels of IL-23 are strongly associated with disease
activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010;69(3):618-23.
22. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-
interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis:
A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis
Rheum 2010;62(4):929-39.
23. Genovese MC, Greenwald MW, Cho CS, et al. A phase 2 study of multiple subcutaneous doses
of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two
populations: Naive to biologic therapy or inadequate responders to tumor necrosis factor alpha
inhibitors. Arthritis Rheum 2011;63(10):S1017.
24. Genovese MC, Durez P, Richards HB, et al. E cacy and safety of secukinumab in patients with
rheumatoid arthritis: a phase II, dose- nding, double-blind, randomised, placebo controlled
study. Ann Rheum Dis 2013;72(6):863-9.
25. AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate.
Available at ClinicalTrials.gov (last accessed 19 January 2013).
26. Krausz S, Boumans MJ, Gerlag DM, et al. Brief report: a phase IIa, randomized, double-blind,
placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in
patients with rheumatoid arthritis. Arthritis Rheum 2012;64(6):1750-5.
27. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The e cacy and safety of rituximab
in patients with active rheumatoid arthritis despite methotrexate treatment: results of a
phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum
2006;54(5):1390-400.
28. Tak PP, Mease PJ, Genovese MC, et al. Safety and e cacy of ocrelizumab in patients with
rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor
inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled,
parallel-group phase III trial. Arthritis Rheum 2012;64(2):360-70.
29. Stohl W, Gomez-Reino J, Olech E, et al. Safety and e cacy of ocrelizumab in combination with
methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann
Rheum Dis 2012;71(8):1289-96.
30. Rigby W, Tony HP, Oelke K, et al. Safety and e cacy of ocrelizumab in patients with rheumatoid
arthritis and an inadequate response to methotrexate: results of a forty-eight-week
randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum
2012;64(2):350-9.
31. van Meerten T, Rozemuller H, Hol S, et al. HuMab-7D8, a monoclonal antibody directed against
the membrane-proximal small loop epitope of CD20 can e ectively eliminate CD20 low
expressing tumor cells that resist rituximab-mediated lysis. Haematologica 2010;95(12):2063-71.
32. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal
antibodies is linked to unique epitopes on CD20. J Immunol 2006;177(1):362-71.
33. Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-CD20 monoclonal
antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to
methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis
2011;70(12):2119-25.
34. A Safety and E cacy Study of LymphoStat-BTM (Monoclonal Anti-BLyS Antibody) in Subjects
With Rheumatoid Arthritis (RA). Available at ClinicalTrials.gov (last accessed 19 January 2013).
35. Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid
arthritis and an inadequate response to tumor necrosis factor antagonist therapy:
results of a phase II, randomized, placebo-controlled, dose- nding trial. Arthritis Rheum
2011;63(7):1793-803.
36. van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid
arthritis and an inadequate response to methotrexate: results of a phase II, randomized,
placebo-controlled trial. Arthritis Rheum 2011;63(7):1782-92.
37. Genovese MC, Bojin S, Biagini IM, et al. Tabalumab in rheumatoid arthritis patients with an
inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized,
placebo-controlled trial. Arthritis Rheum 2013;65(4):880-9.
38. Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-BAFF monoclonal
antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF
inhibitors. Ann Rheum Dis 2013;72(9):1461-8.
39. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the
interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis
who had an incomplete response to methotrexate. Arthritis Rheum 2006;54(9):2817-29.
40. Huizinga TW, Kivitz AJ, Rell-Bakalarska M, et al. Sarilumab for the treatment of moderate-
to-severe rheumatoid arthritis: results of a phase 2, randomized, double-blind, placebo-
controlled, international study. Ann Rheum Dis 2012;71(Suppl3):60.
41. Hsu B, Sheng S, Weinblatt ME, et al. Results from a 2-part, proof-of-concept, dose-ranging,
randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-
IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate
therapy. Ann Rheum Dis 2012;71(Suppl3):188.
42. A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered
Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy
(SIRROUND). Available at ClinicalTrials.gov (last accessed 19 January 2013).
43. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant
human interleukin-1 receptor antagonist, in combination with methotrexate: results of a
twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis
Rheum 2002;46(3):614-24.
44. Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical
improvement following treatment with anakinra (recombinant human interleukin-1 receptor
antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-
blind, placebo-controlled trial. Arthritis Rheum 2002;46(11):2838-46.
45. Alten R, Gomez-Reino J, Durez P, et al. E cacy and safety of the human anti-IL-1beta
monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II,
dose- nding study. BMC Musculoskelet Disord 2011;12:153.
46. Safety and E cacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With
Early Rheumatoid Arthritis. Available at ClinicalTrials.gov (last accessed 19 January 2013).
47. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with
rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005;52(9):2686-92.
48. Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis: a
double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58(7):1931-9.
49. Fleishaker DL, Garcia Meijide JA, Petrov A, et al. Maraviroc, a chemokine receptor-5 antagonist,
fails to demonstrate e cacy in the treatment of patients with rheumatoid arthritis in a
randomized, double-blind placebo-controlled trial. Arthritis Res Ther 2012;14(1):R11.
50. van Kuijk AW, Vergunst CE, Gerlag DM, et al. CCR5 blockade in rheumatoid arthritis:
a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis
2010;69(11):2013-6.
51. Tak PP, Balanescu A, Tseluyko V, et al. Chemokine receptor CCR1 antagonist CCX354-C treatment
for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum
Dis 2013;72(3):337-44.
52. Haringman JJ, Kraan MC, Smeets TJ, et al. Chemokine blockade and chronic in ammatory
disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis
2003;62(8):715-21.
53. O'Shea J J. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 2004;63
Suppl 2:ii67-ii71.
54. Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm
2012;69(24):2120.
55. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK
inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with
active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic
drugs. Arthritis Rheum 2012;64(3):617-29.
56. Keystone E, Taylor P, Genovese M, et al. 12-Week results of a phase 2B dose-ranging study
of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional
DMARDS in patients with rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl3):152.
57. Williams W, Scherle P, Shi J, et al. A Randomized placebo-controlled study of INCB018424, a
selective janus kinase 1 & 2 (JAK1 & 2) inhibitor in rheumatoid arthritis (RA). Arthritis Rheum
2008;58(9):S431.
58. Vanhoutte F, Mazur M, Van der Aa A, et al. Selective JAK1 inhibition in the treatment of
rheumatoid arthritis: Proof of concept with GLPG0634. Arthritis Rheum 2012;64(10):S1051-S.
59. Fleischmann R, Spencer-Green GT, Fan F, et al. Dose ranging study of VX-509, An oral selective
JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Arthritis
Rheum 2011;63(12):4042.
60. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with
a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum
2008;58(11):3309-18.
61. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment
of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in
patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis
Rheum 2011;63(2):337-45.
62. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction
pathways activated by stress and in ammation. Physiol Rev 2001;81(2):807-69.
63. Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis
on the Methotrexate Background. Available at ClinicalTrials.gov (last accessed 19 January
2013).
64. A Study To Evaluate The Safety And Pharmacokinetic Pro le Of A P38 Inhibitor (PH-797804)
In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate. Available at
ClinicalTrials.gov (last accessed 19 January 2013).